Inclusion Criteria:

          -  Age ≥18 years.

          -  Patients with histologically- or cytologically-proven, surgically unresectable,
             locally advanced pancreatic adenocarcinoma.

          -  If the patient does not have a diagnostic biopsy that is adequate for review at our
             institution, the patient must agree to a research core biopsy to be performed at Johns
             Hopkins.

          -  If the patient's available imaging is not adequate for review by our institution, the
             patient must agree to a repeat imaging to be performed at Johns Hopkins.

          -  Patients cannot have had any prior therapy for the locally advanced pancreatic
             adenocarcinoma.

          -  ECOG performance status 0 or 1

          -  Life expectancy greater than 3 months.

          -  Able to swallow pills or capsules.

          -  Patient must have adequate organ function defined by the study-specified laboratory
             tests.

          -  Patients must be eligible to receive FOLFIRINOX-based chemotherapy.

          -  Patients must be willing to be treated with stereotactic body radiation therapy (SBRT)
             only at Johns Hopkins Hospital.

          -  Patients must be willing to undergo a core biopsy of the pancreatic cancer.

          -  Patients must be willing to undergo a biopsy of the pancreatic cancer if the patient
             is not deemed a surgical candidate during the pre-surgical evaluation.

          -  Must use acceptable form of birth control while on study.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Have had non-FOLFIRINOX-based chemotherapy for the pancreatic cancer.

          -  Have received any anti-neoplastic biologics, vaccines or hormonal treatment, including
             investigational drugs, within 28 days of the first dose of study.

          -  History of past treatment with immunotherapy agents prior to initial enrollment into
             this study (including, but not limited to: IL-2, interferon, anti-PD-1, anti-PD-L1,
             anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, anti-CTLA-4 or anti-CCR2/5 drugs).

          -  Have had prior organ or tissue allograft or allogeneic bone marrow transplantation,
             including corneal transplants.

          -  Is currently participating or has participated in a study of an investigational agent
             or using an investigational device for the treatment of cancer.

          -  Current use of immunosuppressive medications within 14 days prior to study
             medications.

          -  Have received any vaccine within 14 days prior to study medications.

          -  Receiving growth factors including, but not limited to, granulocyte-colony stimulating
             factor (G-CSF), GM-CSF, erythropoietin, within 14 days of the first dose of study
             medication.

          -  History of any autoimmune disease. Patients with thyroid disease will be allowed.

          -  Has a history of (non-infectious) pneumonitis or current pneumonitis.

          -  Has a pulse oximetry < 92% on room air.

          -  Requires the use of home oxygen.

          -  Patients with uncontrolled intercurrent illness including, but not limited to,
             myocardial infarction or stroke/transient ischemic attack within the past 6 months,
             uncontrolled infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  12-lead electrocardiogram with QRS ≥ 120 msec, except right bundle branch block ; QTcF
             (QT corrected for heart rate using Fridericia's method) ≥ 480 msec, except right
             bundle branch block

          -  Has an active infection requiring systemic therapy.

          -  Infection with HIV or hepatitis B or C.

          -  Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder
             cancer, early stage prostate cancer, or carcinoma in situ of the cervix.

          -  Current or recent (within 3 months of study treatment administration) gastrointestinal
             disease that could impact the absorption of study treatment.

          -  Any gastrointestinal surgery that is likely impact upon the absorption of study
             treatment.

          -  Inability to tolerate oral medication.

          -  Unable to have blood drawn.

          -  Have had surgery within 28 days of the first dose of study medication.

          -  Prior use of strong/moderate CYP3A4 inhibitors or inducers within 28 days of the first
             dose of BMS-813160.

          -  Prior use of Class I antiarrhythmics within 28 days of first dose of study medication.

          -  Has ascites requiring medical management.

          -  Presence of duodenal or gastric invasion by the tumor.

          -  Hypersensitivity reaction to any monoclonal antibody.

          -  Known allergy or hypersensitivity to study drugs or any of their components of the
             study arm that participant is enrolling.

          -  Woman who are pregnant or breastfeeding.

          -  Patient is unwilling or unable to follow the study schedule for any reason.